Brought to you by 
MorphoSys and P&U in discovery agreement worth up to $50.5mm
13 Jul 1999
Executive Summary
MorphoSys (German biotech) and Pharmacia & Upjohn will collaborate for 6 years to find antibody-based drugs and characterize new targets. P&U gets non-exclusive access to Morphosys' Hu-CAL antibody library and SIP phage-based screening system.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MorphoSys and P&U in discovery agreement worth up to $50.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice